The Italy Blood Glucose Monitor Market was valued at $215.9 Million in 2025 and projected to reach to $295.2 Million by 2030, representing a compound annual growth rate of 6.5%. Italy's blood glucose monitor market is positioned for moderate but consistent growth through 2030, supported by demographic trends and healthcare infrastructure investments.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Italy's blood glucose monitor market is valued at USD 215.9 million in 2025 and is projected to reach USD 295.2 million by 2030, representing a steady CAGR of 6.5% over the forecast period.
Italy has one of Europe's oldest populations, with over 23% aged 65+. This demographic shift significantly increases diabetes prevalence and demand for continuous glucose monitoring and point-of-care testing devices.
The Italian healthcare system prioritizes chronic disease management and reimbursement for glucose monitoring solutions, creating favorable conditions for market expansion and device adoption across public and private sectors.
Italy's diabetes incidence continues to rise, with approximately 3.2 million diagnosed cases. This growing patient base drives sustained demand for both traditional and advanced glucose monitoring technologies.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | NON-INVASIVE PRODUCTS (Product Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.1% from 2025 to 2030 |
| Largest Segment | DIABETES MANAGEMENT (Application) |
| Market Size Base Year (Billions) | ~USD 16.44 (2025) |
| Revenue Forecast (Billions) | ~USD 25.41 (2030) |
| Segments Covered | Product Type, Type, Test Site, Application, End User |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS & CLINICS | 54.8 | 56.1 | 57.8 | 58.9 | 61.4 | 63.5 | 65.8 | 68.4 | 3.4 |
| OTHER END USERS | 32.8 | 34.6 | 36.7 | 38.4 | 41.2 | 43.9 | 46.8 | 50 | 6.4 |
| SELF/HOME CARE | 367.7 | 392.8 | 422.3 | 448.9 | 487.6 | 526.3 | 569.2 | 616.8 | 7.9 |
| TOTAL | 455.4 | 483.5 | 516.8 | 546.2 | 590.2 | 633.6 | 681.8 | 735.2 | 7.3 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Long-term acute care hospitals (LTACHs) – drug-intensive episodes,Inpatient rehabilitation facilities (IRFs) – rehab with chronic comorbidities,Contract rehabilitation and ancillary services, |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| DEXCOM, INC. | United States | Public Company | Dexcom G7 and G7 15 Day,Dexcom G6,Dexcom ONE and ONE+, |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio (incl. Diabetes and Monitoring), |
| SINOCARE | China | Public Company | Blood glucose monitoring systems and strips,Blood pressure and multiparameter testing devices,Hospital and primary healthcare diagnostic solutions, |
| I-SENS, INC. | South Korea | Public Company | Blood glucose meters and strips (human),POCT systems (blood gas, electrolytes, coagulation),Veterinary diagnostics, |
| NIPRO | Japan | Public Company | Dialysis products and services,Injection and infusion / hospital disposables,Pharmaceuticals (generics and kits), |
| NEMAURA MEDICAL INC. | United States | Public Company | sugarBEAT non-invasive CGM,proBEAT wellness and coaching programs,Diabetes prevention and reversal services, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
Kindred Healthcare Inc. is a private healthcare company founded in 1985 and headquartered in the United States. With 64,200 employees, the company operates as a major provider of healthcare services across the nation.
Abbott Laboratories is a public company founded in 1888 and based in the United States. With 115,000 employees, it operates as a diversified healthcare and diagnostics company with a global presence.
Dexcom, Inc. is a publicly traded company founded in 1999 and headquartered in the United States. The company employs 11,050 people and specializes in continuous glucose monitoring technology.
Medtronic is a public company founded in 1949 and based in Ireland. With 95,000 employees, it is a global leader in medical technology and device manufacturing.
Sinocare is a publicly traded company founded in 2002 and headquartered in China. The company employs 5,010 people and operates in the healthcare and medical device sector.
I-SENS, Inc. is a publicly traded company founded in 2000 and based in South Korea. The company employs 887 people and operates in the medical device and diagnostics industry.
Nipro is a publicly traded company founded in 1947 and based in Japan. With 38,593 employees, it manufactures medical devices and pharmaceutical products for global markets.
Nemaura Medical Inc. is a publicly traded company founded in 2009 and headquartered in the United States. With 36 employees, the company develops wearable medical technology solutions.
Terumo Corporation is a publicly traded company founded in 1921 and based in Japan. With 30,591 employees, it manufactures and distributes medical devices and blood products globally.
Italy's blood glucose monitor market is valued at USD 215.9 million in 2025.
Italy's blood glucose monitor market is projected to reach USD 295.2 million by 2030.
Italy's blood glucose monitor market is expected to grow at a CAGR of 6.5% from 2025 to 2030.
Growth in Italy is driven by an aging population, rising diabetes prevalence, healthcare reimbursement policies, and increasing adoption of digital health solutions.
Italy's CAGR of 6.5% is lower than the global CAGR of 9.1%, reflecting regional market maturity and demographic factors specific to Italy.
The study comprised four key activities to estimate the current size of the blood glucose monitor market. First, extensive secondary research was conducted to gather information on the market, including related and parent markets. The next step involved validating these findings, assumptions, and market size estimates through primary research with industry experts across the value chain. Top-down and bottom-up approaches were used to arrive at a comprehensive estimate of the overall market size. Finally, market breakdown and data triangulation techniques were utilized to determine the sizes of segments and subsegments within the market.
The secondary research process involved extensive use of various secondary sources, including directories, databases like Bloomberg Business, Factiva, and D&B Hoovers, as well as white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the blood glucose monitor market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends, down to the finest details. Additionally, a database of leading industry players was created through this secondary research.
In the primary research process, interviews were conducted with various sources from the supply and demand sides to gather qualitative and quantitative information for this report. On the supply side, industry experts were interviewed, including CEOs, vice presidents, marketing & sales directors, technology & innovation directors, and other key executives from prominent companies and organizations involved in the blood glucose monitor market. For the demand side, interviews were conducted with industry experts, purchase and sales managers, doctors, and personnel from research organizations. This primary research was essential to validate market segmentation, identify key players in the industry, and gather insights on important industry trends and market dynamics.
A breakdown of the primary respondents for the blood glucose monitor market is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The research methodology used to estimate the size of the blood glucose monitor market includes the following details. The market sizing was undertaken from the global side.
Country-level Analysis: The size of the blood glucose monitor market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall blood glucose monitor market was obtained from secondary data and validated by primary participants to arrive at the total blood glucose monitor market. Primary participants further validated the numbers.
Geographic Market Assessment (By Region and Country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated by industry experts who were contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall blood glucose monitor market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

After arriving at the overall size from the market size estimation process explained above, the total market was split into several segments and subsegments. The data triangulation and market breakdown procedures explained below were implemented, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for various market segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size was validated using both the top-down and bottom-up approaches.
Blood glucose monitors are medical devices used to measure and monitor blood glucose (sugar) levels in individuals, primarily for the diagnosis and management of diabetes mellitus. These monitors help patients and healthcare professionals assess glycemic control, adjust treatment plans, and prevent diabetes-related complications.
Full forecast, segment splits, and company analysis for all Blood Glucose Monitor Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report